

PHARMION CORP  
Form 8-K  
June 04, 2007

**Table of Contents**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**  
**FORM 8-K**  
**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
**Date of Report (Date of earliest event reported) June 2, 2007**  
**Pharmion Corporation**  
(Exact name of registrant as specified in its charter)

<b>Delaware</b>	<b>000-50447</b>	<b>84-1521333</b>
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
<b>2525 28<sup>th</sup> Street, Boulder, Colorado</b>		<b>80301</b>
(Address of principal executive offices)		(Zip Code)

Registrant's telephone number, including area code **720-564-9100**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01 Other Events

Item 9.01 Financial Statements and Exhibits

SIGNATURES

Exhibit Index

Press Release

Press Release

Press Release

---

**Table of Contents**

**Item 8.01 Other Events.**

On June 2, 2007, Pharmion Corporation (the Company ) announced clinical data from various studies investigating the Company s marketed and pipeline products as presented at the American Society of Clinical Oncology s 43 Annual Meeting.

The press releases are filed as Exhibits 99.1, 99.2 and 99.3 to this Form 8-K and are incorporated herein by reference in their entirety.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

- 99.1 Press Release issued by Pharmion Corporation on June 2, 2007 announcing Clinical Data Presented on Pilot Pharmacokinetic Study of Oral Azacitidine.
- 99.2 Press Release issued by Pharmion Corporation on June 2, 2007 announcing Preliminary Data for MGCD0103.
- 99.3 Press Release issued by Pharmion Corporation on June 2, 2007 announcing Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**PHARMION CORPORATION**

Date: June 4, 2007

By: /s/ **Steven N. Dupont**

Name: Steven N. Dupont  
Title: Vice President and General  
Counsel

- 3 -

---

**Table of Contents**

**Exhibit Index**

- 99.1 Press Release issued by Pharmion Corporation on June 2, 2007 announcing Clinical Data Presented on Pilot Pharmacokinetic Study of Oral Azacitidine.
- 99.2 Press Release issued by Pharmion Corporation on June 2, 2007 announcing Preliminary Data for MGCD0103.
- 99.3 Press Release issued by Pharmion Corporation on June 2, 2007 announcing Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors.

- 4 -